What people are reporting about AOD-9604
7 min read · Uplevel editorial
This article summarizes experiences reported in public online communities including Reddit, longevity forums, and discussion boards. We are not advocating human use of any compound discussed here. Many of the peptides discussed are not FDA-approved for the uses described, and some are explicitly not approved for human or veterinary use. What follows is a synthesis of what people have reported, presented to give readers context on the public conversation — not as guidance, not as evidence of safety or efficacy, and not as a recommendation. Decisions about any compound should be made with a qualified prescribing provider after a full medical evaluation.
The AOD-9604 conversation in online communities is notably different from the conversations around more acutely felt peptides. People discussing BPC-157 often describe noticing effects in joints or gut tissue within weeks. People discussing GLP-1 medications describe appetite suppression that is hard to miss within days. AOD-9604 discussions are quieter and more uncertain in their tone — a thread asking whether the compound is "actually doing anything" will attract as many responses as a thread reporting positive outcomes, and even the positive reports tend to be hedged in ways that are honest rather than triumphant.
The most consistent theme across r/peptides discussions, bodybuilding forums, and longevity boards is that AOD-9604 effects, when they are reported, are gradual and subtle. Users describe noticing changes in body composition over a period of six to twelve weeks rather than days or even two or three weeks. The language is "slightly leaner," "the lower belly softened," "my pants fit differently around the hips." These are reports of incremental change rather than dramatic transformation, and they're consistent across a range of body types and starting points reported in the threads.
A significant part of the community discussion centers on the absence of acute effects. This is almost universally noted by first-time users: AOD-9604 does not produce a perceptible immediate response. There is no appetite suppression, no noticeable change in hunger or food intake — a distinction from GLP-1 experience that comes up repeatedly, usually in the framing of "I don't feel anything, is it working?" Users who have context from GLP-1 medication experiences are often struck by the contrast: semaglutide and tirzepatide produce an unmistakable reduction in appetite that users describe as "the noise going quiet." AOD-9604 produces no equivalent signal. You go about your day unchanged in energy, hunger, and subjective experience — the compound is not felt, it's inferred from eventual changes in the mirror or measurements.
This absence of acute effect shapes how the community discusses compliance and stacking. Because there's no felt response to reinforce use, community reports frequently mention that people discontinue earlier than planned — not due to side effects but due to uncertainty about whether the compound is doing anything. The threads about "how long before I see results" are consistent: most who report positive outcomes describe needing at least six weeks of consistent use to notice anything, and some describe the changes as becoming meaningful only in weeks eight through twelve. The short-protocol users who run four to six weeks and report nothing are common, and it's unclear from community reports whether they stopped too early or whether the compound simply didn't produce a detectable effect in their case.
The administration route debate is active in these communities. Subcutaneous injection versus oral troche is the primary division, and the community discussion reflects genuine uncertainty about which route is more effective. The subcutaneous injection camp argues — reasonably — that most peptides have poor oral bioavailability and that injection is the only route that reliably delivers active compound to circulation. The oral troche camp reports positive outcomes from oral administration and notes that the clinical trials that make AOD-9604 unusual among research peptides were in fact conducted with oral formulations, which suggests at least some oral activity. The honest community consensus, such as it is, seems to be that subcutaneous is probably more reliably effective, that oral troche might work but is less predictable, and that the individual variation in reports from both camps makes it impossible to draw a clean conclusion.
Dose discussions cluster around ranges that differ from the original clinical trials. The oral doses in the Metabolic Pharmaceuticals Phase II program were 1 mg to 10 mg. Subcutaneous injection doses discussed in community threads are often in the range of 200 to 500 micrograms per injection, one to two times daily. The transition from milligram oral dosing to microgram subcutaneous dosing reflects the general principle that injection bypasses first-pass metabolism and gut degradation, but the specific dose relationship has never been established experimentally. Community dosing is empirical and varied, borrowed from forum consensus rather than pharmacokinetic data.
Stacking is nearly ubiquitous in the community reports, to the point where it's genuinely difficult to isolate what AOD-9604 is contributing from what the entire stack is contributing. The most common combinations mentioned are AOD-9604 with GH secretagogues — sermorelin, CJC-1295 with or without ipamorelin — based on the logic that supporting GH pulsatility and adding targeted lipolysis at the beta-3 receptor level might work through complementary mechanisms. Other frequently reported combinations include AOD-9604 alongside GLP-1 medications, often in the framing of using the peptide for more targeted regional fat effects while the GLP-1 handles appetite and overall energy balance. Whether these combinations produce additive, synergistic, or simply coincidental effects is not established in any controlled way — the community doesn't have the tools to isolate variables, and most reporters are making several lifestyle and protocol changes simultaneously.
Reported side effects in community discussions are notably sparse. The most commonly mentioned experiences are injection site reactions — redness, minor irritation — that resolve within hours. A smaller number of users report mild headache in the first few days of use. Serious adverse effects are rarely mentioned in AOD-9604 threads, which is consistent with the Phase II safety data showing a clean profile. The absence of reported problems in the community doesn't establish safety — community reports are notoriously insensitive to delayed or subtle adverse effects, and people who experience significant problems often leave discussions rather than posting about them — but the signal is consistent with what the clinical program found.
The diminishing returns narrative appears in longer community threads. Users who have run multiple AOD-9604 cycles describe the first cycle as producing the most notable body composition changes and subsequent cycles as yielding progressively less. Whether this reflects tachyphylaxis, a return to pre-cycle baselines, or simply the mathematical reality that the first cycle starts from a less lean baseline is not clear from self-reports. The practical consequence in community behavior is that many users describe running AOD-9604 for one or two twelve-week cycles, assessing the results, and then pausing — either cycling off entirely or switching to maintenance protocols.
One practical note worth naming is the community-positivity bias that affects all forum-based discussions of compounds like this. People who see results report them. People who use a compound for several weeks, notice nothing, and conclude it's not working for them are less likely to write detailed posts — they're more likely to quietly stop using it and move on. The community discussion therefore systematically overrepresents positive responders. The actual distribution of outcomes — how many users notice meaningful effects versus how many don't — cannot be read from forum activity. This doesn't invalidate the positive reports, but it means the community conversation is not a representative sample of user experience.
The published research, which includes the Phase II clinical trials and a range of preclinical studies, suggests that AOD-9604 produces modest lipolytic effects in the contexts studied. The consumer and community enthusiasm around the compound is larger than what that evidence base comfortably supports. Both things are true simultaneously, and the community reports — while genuinely informative about what people are experiencing and how they're using the compound — cannot substitute for controlled data that doesn't yet exist for the populations and protocols most commonly discussed. This conversation is one input, not a conclusion.
Frequently asked